{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T05:25:41Z","timestamp":1791869141428,"version":"4.3.4"},"reference-count":40,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,4,16]],"date-time":"2024-04-16T00:00:00Z","timestamp":1713225600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100005972","name":"Stiftung Deutsche Krebshilfe","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005972","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","redjournal.org","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Radiation Oncology*Biology*Physics"],"published-print":{"date-parts":[[2024,12]]},"DOI":"10.1016\/j.ijrobp.2024.04.015","type":"journal-article","created":{"date-parts":[[2024,4,15]],"date-time":"2024-04-15T16:14:19Z","timestamp":1713197659000},"page":"1344-1352","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"title":["Involved-site Radiation Therapy is Equally Effective and Less Toxic Than Involved-field Radiation Therapy in Patients Receiving Combined Modality Treatment for Early-stage Unfavorable Hodgkin Lymphoma\u2014An Analysis of the Randomized Phase 3 HD17 Trial of the German Hodgkin Study Group"],"prefix":"10.1016","volume":"120","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3340-0556","authenticated-orcid":false,"given":"Johannes","family":"Rosenbrock","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helen","family":"Kaul","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Oertel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eren","family":"Celik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philipp","family":"Linde","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiaqi","family":"Fan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dennis A.","family":"Eichenauer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul J.","family":"Br\u00f6ckelmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bastian","family":"von Tresckow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carsten","family":"Kobe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Markus","family":"Dietlein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Fuchs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Borchmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hans Theodor","family":"Eich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Baues","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijrobp.2024.04.015_bib0001","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1016\/j.ijrobp.2017.10.015","article-title":"Comparison of 36 Gy, 20 Gy, or no radiation therapy after 6 cycles of EBVP chemotherapy and complete remission in early-stage Hodgkin lymphoma without risk factors: Results of the EORT-GELA H9-F intergroup randomized trial","volume":"100","author":"Thomas","year":"2018","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2024.04.015_bib0002","doi-asserted-by":"crossref","first-page":"3495","DOI":"10.1200\/JCO.2006.07.0482","article-title":"Two cycles of doxorubicin, bleomycin, vinblastine, and dacarbazine plus extended-field radiotherapy is superior to radiotherapy alone in early favorable Hodgkin's lymphoma: Final results of the GHSG HD7 trial","volume":"25","author":"Engert","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2024.04.015_bib0003","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/S1470-2045(20)30601-X","article-title":"PET-guided omission of radiotherapy in early-stage unfavourable Hodgkin lymphoma (GHSG HD17): A multicentre, open-label, randomised, phase 3 trial","volume":"22","author":"Borchmann","year":"2021","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ijrobp.2024.04.015_bib0004","doi-asserted-by":"crossref","first-page":"4199","DOI":"10.1200\/JCO.2010.29.8018","article-title":"Intensified chemotherapy and dose-reduced involved-field radiotherapy in patients with early unfavorable Hodgkin's lymphoma: Final analysis of the German Hodgkin Study Group HD11 trial","volume":"28","author":"Eich","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2024.04.015_bib0005","doi-asserted-by":"crossref","first-page":"2835","DOI":"10.1200\/JCO.19.00964","article-title":"Positron emission tomography-guided treatment in early-stage favorable Hodgkin lymphoma: Final results of the international, randomized phase III HD16 trial by the German Hodgkin Study Group","volume":"37","author":"Fuchs","year":"2019","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2024.04.015_bib0006","doi-asserted-by":"crossref","first-page":"1786","DOI":"10.1200\/JCO.2016.68.6394","article-title":"Early positron emission tomography response-adapted treatment in stage I and II Hodgkin lymphoma: Final results of the randomized EORTC\/LYSA\/FIL H10 Trial","volume":"35","author":"Andr\u00e9","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2024.04.015_bib0007","doi-asserted-by":"crossref","first-page":"1598","DOI":"10.1056\/NEJMoa1408648","article-title":"Results of a trial of PET-directed therapy for early-stage Hodgkin's lymphoma","volume":"372","author":"Radford","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ijrobp.2024.04.015_bib0008","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1016\/j.ijrobp.2021.07.1697","article-title":"Involved-field radiation therapy prevents recurrences in the early stages of hodgkin lymphoma in PET-negative patients after ABVD chemotherapy: Relapse analysis of GHSG phase 3 HD16 trial","volume":"111","author":"Baues","year":"2021","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2024.04.015_bib0009","doi-asserted-by":"crossref","DOI":"10.1093\/annonc\/mdy080","article-title":"Hodgkin lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"29","author":"Eichenauer","year":"2018","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ijrobp.2024.04.015_bib0010","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1200\/JCO.1985.3.2.207","article-title":"Extended versus involved fields irradiation combined with MOPP chemotherapy in early clinical stages of Hodgkin's disease","volume":"3","author":"Zittoun","year":"1985","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2024.04.015_bib0011","doi-asserted-by":"crossref","first-page":"2835","DOI":"10.1200\/JCO.2004.12.170","article-title":"ABVD plus subtotal nodal versus involved-field radiotherapy in early-stage Hodgkin's disease: Long-term results","volume":"22","author":"Bonadonna","year":"2004","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2024.04.015_bib0012","doi-asserted-by":"crossref","first-page":"3601","DOI":"10.1200\/JCO.2003.03.023","volume":"21","author":"Engert","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2024.04.015_bib0013","doi-asserted-by":"crossref","first-page":"1916","DOI":"10.1056\/NEJMoa064601","article-title":"Chemotherapy plus involved-field radiation in early-stage Hodgkin's disease","volume":"357","author":"Ferm\u00e9","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ijrobp.2024.04.015_bib0014","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1016\/j.radonc.2006.05.015","article-title":"Involved-node radiotherapy (INRT) in patients with early Hodgkin lymphoma: Concepts and guidelines","volume":"79","author":"Girinsky","year":"2006","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.ijrobp.2024.04.015_bib0015","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/j.radonc.2008.05.012","article-title":"The conundrum of Hodgkin lymphoma nodes: To be or not to be included in the involved node radiation fields. The EORTC-GELA lymphoma group guidelines","volume":"88","author":"Girinsky","year":"2008","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.ijrobp.2024.04.015_bib0016","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.radonc.2005.10.018","article-title":"Site of relapse after chemotherapy alone for stage I and II Hodgkin's disease","volume":"78","author":"Shahidi","year":"2006","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.ijrobp.2024.04.015_bib0017","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1093\/annonc\/13.S1.79","article-title":"The involved field is back: Issues in delineating the radiation field in Hodgkin's disease","volume":"13","author":"Yahalom","year":"2002","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ijrobp.2024.04.015_bib0018","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1016\/j.ijrobp.2013.05.005","article-title":"Modern radiation therapy for Hodgkin lymphoma: Field and dose guidelines from the International Lymphoma Radiation Oncology Group (ILROG)","volume":"89","author":"Specht","year":"2014","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2024.04.015_bib0019","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1016\/j.ijrobp.2020.03.019","article-title":"Involved site radiation therapy in adult lymphomas: An overview of International Lymphoma Radiation Oncology Group guidelines","volume":"107","author":"Wirth","year":"2020","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2024.04.015_bib0020","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1016\/j.ijrobp.2012.08.041","article-title":"Involved node radiation therapy: An effective alternative in early-stage Hodgkin lymphoma","volume":"85","author":"Maraldo","year":"2013","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2024.04.015_bib0021","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/j.ijrobp.2010.09.007","article-title":"Involved-node radiotherapy and modern radiation treatment techniques in patients with Hodgkin lymphoma","volume":"80","author":"Paumier","year":"2011","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2024.04.015_bib0022","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/j.ijrobp.2014.01.041","article-title":"Involved-site image-guided intensity modulated versus 3D conformal radiation therapy in early stage supradiaphragmatic Hodgkin lymphoma","volume":"89","author":"Filippi","year":"2014","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2024.04.015_bib0023","doi-asserted-by":"crossref","first-page":"5170","DOI":"10.1200\/JCO.2007.15.1001","article-title":"Involved-nodal radiation therapy as a component of combination therapy for limited-stage Hodgkin's lymphoma: A question of field size","volume":"26","author":"Campbell","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2024.04.015_bib0024","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1200\/JCO.22.02355","article-title":"Nivolumab and doxorubicin, vinblastine, and dacarbazine in early-stage unfavorable Hodgkin lymphoma: Final analysis of the randomized German Hodgkin Study Group phase II NIVAHL trial","volume":"41","author":"Br\u00f6ckelmann","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2024.04.015_bib0025","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1200\/JCO.21.01281","article-title":"Brentuximab vedotin plus AVD for first-line treatment of early-stage unfavorable Hodgkin lymphoma (BREACH): A multicenter, open-label, randomized, phase II trial","volume":"41","author":"Fornecker","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2024.04.015_bib0026","doi-asserted-by":"crossref","first-page":"2257","DOI":"10.1200\/JCO.21.00108","article-title":"Brentuximab vedotin combined with chemotherapy in patients with newly diagnosed early-stage, unfavorable-risk Hodgkin lymphoma","volume":"39","author":"Kumar","year":"2021","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.ijrobp.2024.04.015_bib0027","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1016\/j.ijrobp.2023.05.011","article-title":"A quality control study on involved node radiation therapy in the European Organisation for Research and Treatment of Cancer\/Lymphoma Study Association\/Fondazione Italiana Linfomi H10 trial on stages I and II Hodgkin lymphoma: Lessons learned","volume":"117","author":"Aleman","year":"2023","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2024.04.015_bib0028","article-title":"Radiation therapy in the German Hodgkin Study Group HD 16 and HD 17 trials: Quality assurance and dosimetric analysis for Hodgkin lymphoma in the modern era","volume":"8","author":"Oertel","year":"2023","journal-title":"Adv Radiat Oncol"},{"key":"10.1016\/j.ijrobp.2024.04.015_bib0029","doi-asserted-by":"crossref","first-page":"1791","DOI":"10.1016\/S0140-6736(11)61940-5","article-title":"Reduced-intensity chemotherapy and PET-guided radiotherapy in patients with advanced stage Hodgkin's lymphoma (HD15 trial): A randomised, open-label, phase 3 non-inferiority trial","volume":"379","author":"Engert","year":"2012","journal-title":"Lancet"},{"key":"10.1016\/j.ijrobp.2024.04.015_bib0030","first-page":"23","article-title":"Hodgkin's disease and other malignant lymphomas","volume":"113","author":"Rosenberg","year":"1970","journal-title":"Calif Med"},{"key":"10.1016\/j.ijrobp.2024.04.015_bib0031","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1200\/JCO.1988.6.2.239","article-title":"Clinical stages I and II Hodgkin's disease: A specifically tailored therapy according to prognostic factors","volume":"6","author":"Carde","year":"1988","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2024.04.015_bib0032","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.clon.2012.07.011","article-title":"Recommendations for the use of radiotherapy in nodal lymphoma","volume":"25","author":"Hoskin","year":"2013","journal-title":"Clin Oncol (R Coll Radiol)"},{"key":"10.1016\/j.ijrobp.2024.04.015_bib0033","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1007\/s00066-008-1882-7","article-title":"Involved-node radiotherapy in early-stage Hodgkin's lymphoma. Definition and guidelines of the German Hodgkin Study Group (GHSG)","volume":"184","author":"Eich","year":"2008","journal-title":"Strahlenther Onkol"},{"key":"10.1016\/j.ijrobp.2024.04.015_bib0034","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1093\/jnci\/djaa194","article-title":"Long-term cause-specific mortality in Hodgkin lymphoma patients","volume":"113","author":"de Vries","year":"2021","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.ijrobp.2024.04.015_bib0035","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.ijrobp.2016.10.004","article-title":"Secondary breast cancer risk by radiation volume in women with Hodgkin lymphoma","volume":"97","author":"Conway","year":"2017","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2024.04.015_bib0036","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/j.ejmp.2018.12.036","article-title":"Probability of carcinogenesis due to involved field and involved site radiation therapy techniques for supra- and infradiaphragmatic Hodgkin's disease","volume":"57","author":"Kourinou","year":"2019","journal-title":"Phys Med"},{"key":"10.1016\/j.ijrobp.2024.04.015_bib0037","doi-asserted-by":"crossref","first-page":"3866","DOI":"10.1002\/mp.12327","article-title":"Second cancer risk assessments after involved-site radiotherapy for mediastinal Hodgkin lymphoma","volume":"44","author":"Mazonakis","year":"2017","journal-title":"Med Phys"},{"key":"10.1016\/j.ijrobp.2024.04.015_bib0038","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/j.clon.2015.03.005","article-title":"Involved node, site, field and residual volume radiotherapy for lymphoma: A comparison of organ at risk dosimetry and second malignancy risks","volume":"27","author":"Murray","year":"2015","journal-title":"Clin Oncol (R Coll Radiol)"},{"key":"10.1016\/j.ijrobp.2024.04.015_bib0039","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.658358","article-title":"Involved site radiotherapy extends time to premature menopause in infra-diaphragmatic female Hodgkin lymphoma patients - an analysis of GHSG HD14- and HD17-patients","volume":"11","author":"Rosenbrock","year":"2021","journal-title":"Front Oncol"},{"key":"10.1016\/j.ijrobp.2024.04.015_bib0040","doi-asserted-by":"crossref","first-page":"2113","DOI":"10.1093\/annonc\/mdt156","article-title":"Estimated risk of cardiovascular disease and secondary cancers with modern highly conformal radiotherapy for early-stage mediastinal Hodgkin lymphoma","volume":"24","author":"Maraldo","year":"2013","journal-title":"Ann Oncol"}],"container-title":["International Journal of Radiation Oncology*Biology*Physics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0360301624005145?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0360301624005145?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,11,14]],"date-time":"2024-11-14T23:27:31Z","timestamp":1731626851000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0360301624005145"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12]]},"references-count":40,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2024,12]]}},"alternative-id":["S0360301624005145"],"URL":"https:\/\/doi.org\/10.1016\/j.ijrobp.2024.04.015","relation":{},"ISSN":["0360-3016"],"issn-type":[{"value":"0360-3016","type":"print"}],"subject":[],"published":{"date-parts":[[2024,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Involved-site Radiation Therapy is Equally Effective and Less Toxic Than Involved-field Radiation Therapy in Patients Receiving Combined Modality Treatment for Early-stage Unfavorable Hodgkin Lymphoma\u2014An Analysis of the Randomized Phase 3 HD17 Trial of the German Hodgkin Study Group","name":"articletitle","label":"Article Title"},{"value":"International Journal of Radiation Oncology*Biology*Physics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijrobp.2024.04.015","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}